Novartis Pharmaceuticals Corp. and Others See FDA Withdraw Approval of 27 New Drug Applications and 58 Abbreviated New Drug Applications

Summary

The US Food and Drug Administration (FDA) has withdrawn approval of 27 new drug applications and 58 abbreviated new drug applications from multiple pharmaceutical companies, including Novartis Pharmaceuticals Corp., following written notifications from the applicants that the drug products are no longer commercially available.